These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21510316)

  • 1. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
    Kilickap S; Yalcin S; Ates O; Tekuzman G
    Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
    Ajani JA; Fodor MB; Tjulandin SA; Moiseyenko VM; Chao Y; Cabral Filho S; Majlis A; Assadourian S; Van Cutsem E
    J Clin Oncol; 2005 Aug; 23(24):5660-7. PubMed ID: 16110025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
    Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
    Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
    Yao Z; Guo H; Yuan Y; Zhao Y; Yao S; Xu Y; Liu L; Liu T; Liu Y; Yang S
    J Chemother; 2014 Apr; 26(2):117-21. PubMed ID: 24090813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
    Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Marabotti C; Van Cutsem E;
    J Clin Oncol; 2007 Aug; 25(22):3205-9. PubMed ID: 17664467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
    Roth AD; Fazio N; Stupp R; Falk S; Bernhard J; Saletti P; Köberle D; Borner MM; Rufibach K; Maibach R; Wernli M; Leslie M; Glynne-Jones R; Widmer L; Seymour M; de Braud F;
    J Clin Oncol; 2007 Aug; 25(22):3217-23. PubMed ID: 17664469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience.
    Ben Aharon I; Purim O; Kundel Y; Brenner R; Gordon N; Sulkes A; Brenner B
    Anticancer Drugs; 2012 Mar; 23(3):313-20. PubMed ID: 22241172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
    Sadighi S; Mohagheghi MA; Montazeri A; Sadighi Z
    BMC Cancer; 2006 Dec; 6():274. PubMed ID: 17147808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
    Thuss-Patience PC; Kretzschmar A; Krenn V; Dörken B; Reichardt P
    Onkologie; 2003 Feb; 26(1):63-5. PubMed ID: 12624520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.
    Ajani JA
    Cancer; 2008 Sep; 113(5):945-55. PubMed ID: 18623382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.